Septerna, Inc. (SEPN) - Dilution Analysis

10-Q filing | 44.8M shares outstanding

10-K filing | 44.3M shares outstanding

10-Q filing | 44.3M shares outstanding

10-Q filing | 44.2M shares outstanding

10-Q filing | 43.9M shares outstanding

10-K filing | 44.4M shares outstanding

10-Q filing | 44.4M shares outstanding

S-1/A filing: This S-1/A filing from 2024-10-24 details an offering of 15,277,778 shares of common stock with an underwriter option for an additional 2,291,666 shares, at a price of $18.00 per share, resulting in estimated net proceeds of $250.0 million (or $288.3 million if the underwriter option is fully exercised).

S-1/A filing: The company is filing an S-1/A form to register an offering of common stock. The company intends to use the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, as follows: approximately $54 million to advance the continued development of SEP-786, our lead product candidate from our PTH1R program through completion of a Phase 2 clinical trial in hypoparathyroidism patients, and additional molecules targeting PTH1R; approximately $24 million to advance the development of SEP-631 through completion of a Phase 1 clinical trial, and additional small molecules within our MRGPRX2 program; approximately $41 million for other research and development activities, including our TSHR and incretin receptor programs, other new GPCR programs, and continued innovation of our Native Complex PlatformTM; and the remainder to fund working capital and other general corporate purposes.

S-1 filing: The filing is an S-1 form indicating an offering of common stock, with J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities as underwriters. It mentions an option for underwriters to purchase additional shares and provides information on the use of proceeds, risk factors, and the proposed Nasdaq trading symbol.